---
title: "GKB Ophthalmics Ltd (533212) — Share Price, Financials & Analysis"
symbol: "533212"
company: "GKB Ophthalmics Ltd"
canonical: "https://tapetide.com/stocks/533212"
isin: "INE265D01015"
nse_symbol: "GKB"
bse_code: "533212"
sector: "Healthcare"
industry: "Medical Equipment"
market_cap_cr: 32.74
generated_at: "2026-09-13T19:21:59.007Z"
---

# GKB Ophthalmics Ltd (533212)

Canonical page: https://tapetide.com/stocks/533212

## Company

- **NSE Symbol:** GKB
- **BSE Code:** 533212
- **ISIN:** INE265D01015
- **Sector:** Healthcare
- **Industry:** Medical Equipment
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2010-07-09
- **CEO:** Mr. Krishna Gopal Gupta
- **Employees:** 170
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** gkb.net

## About

Incorporated in 1981, GKB Ophthalmics Ltd is engaged in the manufacture and sale of ophthalmic lenses made up of Glass and 
Plastic.[1]

## Latest Price

- **Price:** ₹64.79
- **Change:** -0.3 (-0.46%)
- **Open:** ₹65
- **Day High:** ₹67
- **Day Low:** ₹63.51
- **Previous Close:** ₹65.09
- **Volume:** 2674
- **As Of:** 2026-09-11T09:59:38+00:00

## Key Fundamentals

Observed at 2026-09-11T04:39:00.152068Z.

- **Market Cap:** ₹32.74 Cr
- **Classification:** Microcap
- **P/E (reported):** 5.9
- **EPS (TTM):** ₹-3.81
- **Book Value:** ₹104.82
- **Price to Book:** 0.62
- **Dividend Yield:** 0%
- **ROE:** 5.52%
- **ROCE:** 9.48%
- **Debt to Equity:** 0.67
- **Revenue (yearly):** ₹151.3 Cr
- **Net Income:** ₹3 Cr
- **EBITDA:** ₹10.9 Cr
- **52-Week High:** ₹74
- **52-Week Low:** ₹60.3
- **RSI (14):** 51.53

## Tapetide Score

- **Score:** 47 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 35.6 (of 4473 scored stocks)
- **Confidence:** 95%
- **Data coverage:** 90%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 25.83 | 9% |
| growth | 9.44 | 9% |
| momentum | 73.48 | 12% |
| ownership | 50.11 | 24% |
| quality | 38.28 | 22% |
| valuation | 61.28 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 3.74% over past five years.
- Company has a low return on equity of -18.5% over last 3 years.
- Earnings include an other income of Rs.4.58 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -8.03%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -11.08% | -190.28% | -175.15% |
| ebitda margin growth | 41.67% | -643.94% | 209.48% | -13.81% |
| net income growth | 72.73% | -142.25% | 10% | -26% |
| revenue growth | 10.46% | 37.17% | -3% | 4% |
| roce | 59.37% | -236.8% | -840.63% | 1.72% |
| roe | 65.18% | -144.02% | -3.89% | 91.67% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7.27 | 6.84 | 7.36 | 8.62 | 8.26 | 7.45 | 8.43 | 8.77 | 6.11 | 4.36 | 6.4 | 6.4 |
| Expenses | 8.12 | 7.85 | 7.77 | 9.05 | 9.3 | 8.27 | 9.61 | 9.62 | 6.74 | 5.41 | 6.85 | 6.65 |
| Operating Profit | -0.85 | -1.01 | -0.41 | -0.43 | -1.04 | -0.82 | -1.18 | -0.85 | -0.63 | -1.05 | -0.45 | -0.25 |
| OPM % | -11.69 | -14.77 | -5.57 | -4.99 | -12.59 | -11.01 | -14 | -9.69 | -10.31 | -24.08 | -7.03 | -3.91 |
| Other Income | 0.07 | 1.72 | 0.2 | 0.09 | 0.06 | 1.81 | 0.01 | 0.07 | 1.37 | 3.24 | -0.5 | 0.47 |
| Interest | 0.38 | 0.36 | 0.48 | 0.41 | 0.4 | 0.48 | 0.6 | 0.68 | 0.57 | 0.6 | 0.32 | 0.3 |
| Depreciation | 0.65 | 0.66 | 0.64 | 0.65 | 0.66 | 0.67 | 0.66 | 0.67 | 0.68 | 0.68 | 0.66 | 0.66 |
| Profit before tax | -1.81 | -0.31 | -1.33 | -1.4 | -2.04 | -0.16 | -2.43 | -2.13 | -0.51 | 0.91 | -1.93 | -0.74 |
| Tax % | 0 | 0 | 3.01 | 0.71 | 0.49 | 6.25 | 1.65 | 0.94 | 3.92 | -7.69 | -2.07 | -32.43 |
| Net Profit | -1.81 | -0.31 | -1.37 | -1.41 | -2.05 | -0.17 | -2.48 | -2.14 | -0.52 | 0.98 | -1.88 | -0.5 |
| EPS in Rs | -3.59 | -0.62 | -2.72 | -2.8 | -4.07 | -0.34 | -4.92 | -4.25 | -1.03 | 1.94 | -3.73 | -0.99 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 37.43 | 30.47 | 25.56 | 21.34 | 27.05 | 27.73 | 31.18 | 32.75 | 25.64 | 23.27 |
| Expenses | 38.41 | 31.52 | 26.29 | 21.63 | 27.44 | 28.82 | 32.46 | 36.22 | 28.61 | 25.65 |
| Operating Profit | -0.98 | -1.05 | -0.73 | -0.29 | -0.39 | -1.09 | -1.28 | -3.47 | -2.97 | -2.38 |
| OPM % | -2.62 | -3.45 | -2.86 | -1.36 | -1.44 | -3.93 | -4.11 | -10.6 | -11.58 | -10.23 |
| Other Income | 1.05 | 2.62 | 1.38 | 2.33 | 1.91 | 2.09 | 2.08 | 1.97 | 4.18 | 4.58 |
| Interest | 1.23 | 1.39 | 1.35 | 1.34 | 1.34 | 1.5 | 1.59 | 1.89 | 2.17 | 1.79 |
| Depreciation | 1.58 | 3.43 | 3.47 | 2.99 | 2.49 | 2.54 | 2.59 | 2.64 | 2.69 | 2.68 |
| Profit before tax | -2.74 | -3.25 | -4.17 | -2.29 | -2.31 | -3.04 | -3.38 | -6.03 | -3.65 | -2.27 |
| Tax % | -6.2 | -14.77 | 0 | -7.86 | 0 | -5.26 | 1.18 | 1.16 | -2.19 | — |
| Net Profit | -2.58 | -2.78 | -4.17 | -2.11 | -2.31 | -2.88 | -3.42 | -6.11 | -3.57 | -1.92 |
| EPS in Rs | -6.21 | -5.99 | -8.27 | -4.19 | -4.58 | -5.71 | -6.78 | -12.12 | -7.08 | -3.81 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4.15 | 4.15 | 4.64 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 |
| Reserves | 25.44 | 22.78 | 30.03 | 30.21 | 27.73 | 25.36 | 22.48 | 18.95 | 12.63 | 9.28 |
| Borrowings | 7.19 | 9.93 | 10.05 | 10.04 | 11.97 | 11.75 | 11.22 | 11.08 | 18.09 | 9.54 |
| Other Liabilities | 10.22 | 8.57 | 10.45 | 11.4 | 12.13 | 11.74 | 10.41 | 13.32 | 13.72 | 12.75 |
| Total Liabilities | 47 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 49.48 | 36.61 |
| Fixed Assets | 16.43 | 16.98 | 24.29 | 24.83 | 22.28 | 21.27 | 17.28 | 15.89 | 14.44 | 12.49 |
| CWIP | 0.57 | 0.24 | 0 | 0 | 1.23 | 3.29 | 3.82 | 3.78 | 3.78 | 3.78 |
| Investments | 3.77 | 0.66 | 0.32 | 3.21 | 12.22 | 11.9 | 11.9 | 11.9 | 11.9 | 0.19 |
| Other Assets | 26.23 | 27.55 | 30.56 | 28.65 | 21.14 | 17.43 | 16.15 | 16.82 | 19.36 | 20.15 |
| Total Assets | 47 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 49.48 | 36.61 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -4.2 | -3.71 | 5.31 | 6.13 | 2.11 | 2.33 | -1.14 | 1.36 | -5.04 | -1.48 |
| Cash from Investing Activity | 5.5 | 2.28 | -8.63 | -5.68 | -11.52 | -0.83 | 2.4 | 0.37 | -0.16 | 12.21 |
| Cash from Financing Activity | -1.29 | 1.41 | 9.21 | 3.31 | 0.61 | -1.5 | -2.03 | -1.74 | 5.12 | -10.72 |
| Net Cash Flow | 0 | -0.02 | 5.88 | 3.76 | -8.8 | 0 | -0.78 | 0 | -0.07 | 0 |
| Free Cash Flow | -9.08 | -5.27 | -4.35 | 2.44 | -1.2 | -1.34 | 0.25 | 0.16 | -6.43 | -2.06 |
| CFO/OP | 725 | 366 | -509 | -841 | -728 | -600 | 101 | -107 | 144 | 49 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 66 | 101.81 | 129.49 | 148.08 | 127.25 | 80.96 | 64.23 | 80.3 | 83.48 | 73.74 |
| Inventory Days | 283.5 | 264.1 | 154.9 | 133.5 | 256.82 | 141.86 | 161.81 | 102.38 | 120.22 | 143.13 |
| Days Payable | 106.91 | 84.89 | 171.32 | 222.98 | 251.31 | 158.86 | 139.11 | 157.83 | 137.81 | 139.26 |
| Cash Conversion Cycle | 242.59 | 281.01 | 113.07 | 58.61 | 132.77 | 63.96 | 86.93 | 24.86 | 65.88 | 77.61 |
| Working Capital Days | 80.72 | 94.59 | -7.67 | -56.12 | -86.38 | -85.68 | -60.02 | -85.22 | -70.1 | -34.17 |
| ROCE % | -0.77 | -4.13 | -8.09 | -6.29 | 0.13 | -2.14 | -3.96 | -4.96 | -11.8 | 0.47 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.86% | 50.88% | 50.93% | 50.95% | 50.95% | 50.98% | 50.99% | 51.06% | 51.06% | 51.13% | 51.13% | 51.15% |
| FIIs | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% |
| DIIs | 0.01% | 0.01% | 0.01% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 36.01% | 36.04% | 36.04% | 36.64% | 36.34% | 36.96% | 37.36% | 37.22% | 37.23% | 38.55% | 38.52% | 38.97% |
| Others | 11.34% | 11.28% | 11.23% | 10.63% | 10.93% | 10.27% | 9.87% | 9.94% | 9.93% | 8.53% | 8.57% | 8.09% |
| No. of Shareholders | 2115 | 2233 | 2370 | 2690 | 2510 | 2539 | 2538 | 2550 | 2601 | 2661 | 2634 | 2557 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 65.84 | Sell |
| EMA (10) | 65.61 | Sell |
| SMA (20) | 64.84 | Sell |
| EMA (20) | 64.48 | Buy |
| SMA (50) | 61.29 | Buy |
| EMA (50) | 62.83 | Buy |
| SMA (100) | 63.53 | Buy |
| EMA (100) | 62.26 | Buy |
| SMA (200) | 59.66 | Buy |
| EMA (200) | 63.07 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 51.87 | Neutral |
| MACD (12,26,9) | 1.49 | Sell |
| Stochastic (14,3,3) | 37.49 | Neutral |
| ADX (14) | 15.48 | Neutral |
| Williams %R (14) | -67.23 | Neutral |
| ATR (14) | 3.97 | High Volatility |
| ROC (12) | 2.84 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 46.14 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ee02e2f-05e2-4f34-b608-d0a43d5db9a6.pdf) |
| 2026-08-25 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6160ed27-e843-4635-bc19-fed9aa3c249e.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2136247f-3a58-45f6-9722-460a66483b96.pdf) |
| 2026-08-12 | [Board Meeting Outcome for Outcome Of The Board Meeting Of GKB Ophthalmics Ltd. Held On August 12 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8065e58-d547-4aeb-8ccf-a3b1946a510b.pdf) |
| 2026-08-01 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab25c920-141a-467f-a4b1-71b7b96ffd30.pdf) |
| 2026-07-31 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d40b3f87-486d-4653-8265-ceb4b956d1a1.pdf) |
| 2026-07-31 | [Notice For Book Closure](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41a61a16-a173-4274-a294-670f0a403902.pdf) |
| 2026-07-31 | [Disclosure Of Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015("Listing Regulations)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5223cced-b71d-411d-8265-955697fefc78.pdf) |
| 2026-07-25 | [Board Meeting Intimation for Approval Of Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfe170e1-4b95-4732-ac19-1ea6c17a917c.pdf) |
| 2026-07-14 | [Disclosure Of Information Pursuant To Regulation 30- Update On Case No. 32/09 Filed For Adjudication Of Charter Of Demands](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45967af9-3702-4664-b70b-3a642b072a2a.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c014eb23-749a-47d4-a52b-1367622667c9.pdf) |
| 2026-05-27 | [Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78d1245f-9f73-48f1-988f-d3dcec72ff03.pdf) |
| 2026-02-12 | [December 31 2025 _Unaudited Standalone And Consolidated Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2528eb9d-5ce2-4f89-b44f-77fbb702c506.pdf) |
| 2025-11-14 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=409683c5-b92d-4247-8db7-7fc9d4891c2d.pdf) |
| 2025-08-14 | [GKB Ophthalmics Limited - Unaudited Standalone & Consolidated Financial Results - June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7e75e0f-beaa-48dd-9778-1ba36238fd42.pdf) |
| 2025-05-30 | [GKB- Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61400ce0-fe91-495b-93f0-477497067bf5.pdf) |
| 2025-02-13 | [GKB- Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a52bfb5-3b4a-4541-a9f0-6ee68d50d33c.pdf) |
| 2024-11-14 | [Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93280002-bdb2-4fd1-8845-f0b2c910ac4b.pdf) |
| 2024-08-13 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce313259-c893-4d86-a144-84ae497d1e21.pdf) |
| 2024-05-30 | [GKB - Audited Standalone And Consolidated Financials For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8080fdef-da57-4835-925a-c60a52023983.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Independent Directors meeting on March 18, 2026 to review board, chairman performance and information flow. | [Notice Of The Independent Directors'' Meeting 9 Mar - Independent Directors meeting on March 18, 2026 to review board, chairman performance and information flow.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bef1a3cd-02ba-46a0-aac4-9e7dadff665c.pdf) |
| 7 Apr - Company confirms SEBI large corporate circular is not applicable. | [Non Applicability Of Circular No. SEBI/HO/DDHS/CIR/P/2018/144, Dated November 26, 2018 7 Apr - Company confirms SEBI large corporate circular is not applicable.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5899c9f3-8a7f-4438-9778-5958c3bd45b2.pdf) |
| 7 Apr - Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the … | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2df714b4-f17b-46c8-b0de-a058c5b22102.pdf) |
| 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results. | [Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31, 2026. 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7d630bd8-270f-4a2e-9b1e-8dad9940b1ad.pdf) |
| 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results. | [Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31, 2026. 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7d630bd8-270f-4a2e-9b1e-8dad9940b1ad.pdf) |
| 30 Jan - Board meeting Feb 12, 2026 to approve Q3/9M Dec 31,2025 unaudited results; trading window reopens after 48 hours. | [Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025. 30 Jan - Board meeting Feb 12, 2026 to approve Q3/9M Dec 31,2025 unaudited results; trading window reopens after 48 hours.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/61557ae9-25ae-4902-a119-a79d68a80a43.pdf) |
| 30 Jan - Audio recording of Manappuram Q3 FY2025-26 results call (29-Jan-2026) uploaded on company website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Jan - Audio recording of Manappuram Q3 FY2025-26 results call (29-Jan-2026) uploaded on company website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/067bb511-557f-4ce5-bbaf-f6667bcbbdce.pdf) |
| 29 Jan - Manoj Kumar VR resigns effective March 31, 2026; Aparna Menon appointed Company Secretary effective April 1, 2026. | [Appointment of Company Secretary and Compliance Officer 29 Jan - Manoj Kumar VR resigns effective March 31, 2026; Aparna Menon appointed Company Secretary effective April 1, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a6367b43-7f85-403c-a12c-acd1ac13fe04.pdf) |
| 25 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2026 results; board meeting date pending. | [Closure of Trading Window 25 Mar - Trading window closed Apr 01, 2026 until 48 hours after audited FY2026 results; board meeting date pending.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/10540ad2-92d2-4e3f-b918-91f7bedb6533.pdf) |
| 25 Feb - CEO Deepak Reddy to take medical leave overseas from Feb 25, 2026 for 90–120 days. | [Update In Relation To Mr. Deepak Reddy, Chief Executive Officer Of The Company 25 Feb - CEO Deepak Reddy to take medical leave overseas from Feb 25, 2026 for 90–120 days.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6b5f3c44-d24c-4515-8729-b7c8b0faadcc.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6edf2abd-3419-49c0-b327-93043bc502c4.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/790f6f95-d056-4502-879c-1ea7ceb265c3.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25406421-0a83-46b0-87b0-95f5281d5868.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dbabd52b-af66-47d7-955f-d8548af5f0e5.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a8350792-d555-4989-a6a9-91ce3294c3b6.pdf) |
| Mar 2025 | [Concall - Mar 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75133bc4-8e70-499e-9d59-d1c82ca523cd.pdf) |
| Feb 2024 | [Concall - Feb 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a1d78c9b-6679-4f4d-a619-9aedbce164f1.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/250e009a-b718-41a2-a901-6db4321dbeb2.pdf) |
| Dec 2015 | [Concall - Dec 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=EC82AEC3_3BD5_4DD0_A5A8_C505F97721B8_175216.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f39b5448-60c7-4d76-ac3d-898cc52db7a4.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d40b3f87-486d-4653-8265-ceb4b956d1a1.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d69daba-3907-4f06-bc75-adaf69fdeb0b.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b022cf14-3928-4db6-8107-e5e71667b3d1.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/87b001dd-251c-403c-8c7f-71c6af85b1c8.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db69f6df-ef36-4463-bdde-2e0a428ad497.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/82ec1820-1726-4b7f-a155-5972321fdcd7.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8c43455f-e567-4f74-ad8e-ded4132a6410.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/531213/74001531213.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/533212/76338533212.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/531213/69512531213_11_09_21.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:21:59.007Z.